104 related articles for article (PubMed ID: 29127747)
1. [Treatment strategy of type 2 diabetes used in Czech Republic after metformin therapy failure].
Svačina Š; Ovesná P; Kuhn M; Nováčková M
Vnitr Lek; 2017; 63(10):647-657. PubMed ID: 29127747
[TBL] [Abstract][Full Text] [Related]
2. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Bailey T
Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
[TBL] [Abstract][Full Text] [Related]
3. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
4. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Jermendy G
Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
[TBL] [Abstract][Full Text] [Related]
5. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
[TBL] [Abstract][Full Text] [Related]
6. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
7. Add-on therapies to metformin for type 2 diabetes.
Shomali M
Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
9. Metformin + saxagliptin for type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].
Doležal T; Kruntorádová K
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S50-3. PubMed ID: 26652966
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of gliflozins versus gliptins for Type 2 Diabetes after metformin failure: a systematic review and network meta-analysis.
Zilli RW; Rached CDA; Silva FPD; Baena RC
Rev Assoc Med Bras (1992); 2020 Apr; 66(4):458-465. PubMed ID: 32578779
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the development of metformin and sulfonylurea prescriptions in the Czech Republic].
Janíčková-Žďarská D; Honěk P; Dušek L; Pavlík T; Kvapil M
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S25-9. PubMed ID: 26652962
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
15. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
16. [The safety of anti-diabetic drugs in heart failure].
Frigy A; Germán-Salló M; Máthé L; Szabó M
Orv Hetil; 2017 Feb; 158(5):163-171. PubMed ID: 28132538
[TBL] [Abstract][Full Text] [Related]
17. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
[TBL] [Abstract][Full Text] [Related]
18. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
20. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Dai X; Wang H; Jing Z; Fu P
Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
